Ursosana ® tablets are used for the following indications:
Active ingredient: ursodeoxycholic acid.
1 coated tablet contains 500 mg of ursodeoxycholic acid.
Excipients: corn starch, corn starch, sodium starch (type A), colloidal silicon dioxide, magnesium stearate, white shell 03B28796 (hypromellose 6, titanium dioxide (E171), macrogol 400).
For patients whose body weight is less than 47 kg or who have difficulty swallowing capsules, it is recommended to use ursodeoxycholic acid in a different dosage form.
pregnant
According to several recorded cases of the use of the preparation by breastfeeding, the content of ursodeoxycholic acid in milk was extremely low, therefore, the development of any adverse events in children receiving such milk should not be expected.
Children
There are no fundamental age restrictions for the use of Ursosan® forte in children, but children weighing less than 47 kg and / or children who have difficulty swallowing are recommended to use ursodeoxycholic acid in a different dosage form.
Drivers
There was no effect on the ability to drive a car and use mechanisms.
In case of an overdose, diarrhea is possible. Other symptoms of overdose are unlikely because the absorption of ursodeoxycholic acid decreases with increasing dose, so most of the dose is excreted in the feces.
From the gastrointestinal tract
Pasty stools or diarrhea have been frequently reported during clinical studies during treatment with ursodeoxycholic acid.
Very rarely, severe abdominal pain in the right hypochondrium was noted during the treatment of PBC.
From the side of the liver and gallbladder
Very rarely, calcification of gallstones is possible during treatment with ursodeoxycholic acid.
During the treatment of advanced stages of PBC, decompensation of liver cirrhosis is very rarely observed, partially decreases after treatment is stopped.
Hypersensitivity reactions
Allergic reactions are very rarely possible, including rash, urticaria.
Ursodeoxycholic acid should not be co-administered with cholestyramine, colestipol, or antacids containing aluminum hydroxide and/or smectite (alumina), as these preparations bind ursodeoxycholic acid in the intestine and thus interfere with its absorption and reduce efficacy. If the use of preparations containing one of these substances is necessary, they must be taken at least 2:00 before or 2:00 after taking the preparation.
Does not require special storage conditions. Keep out of the reach of children.
Shelf life: 4 years.